Eduardo Vianna

Institute For Regenerative Medicine is a non-profit organization. It focuses on regenerative medicine and cell therapy. The company as founded in August 2008 and is headquartered in College Station, TX.

ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland.

Evotec International GmbH develops and provides drugs for the treatment of CNS disorders. It focuses on Alzheimer's disease and other neurological disorders. The company was founded in 1999 and is headquartered in Hamburg, Germany.

Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA.

Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland.

Integra Biosciences AG manufactures and distributes laboratory equipment. Its products include manual, electronic pipettes, micro plate dispensers, peristaltic pump and aspiration systems. The company is headquartered in Zizers, Switzerland.

Neurimmune Holding AG is a Swiss pharmaceutical company that was founded in 2006. The private company is based in Schlieren, Switzerland and has subsidiaries in Switzerland. Neurimmune Holding manufactures pharmaceutical products.

Swiss Biotech Association operates as an industry association. The private company is based in Zurich, Switzerland. Michael Altorfer has been the CEO of the Swiss company since 2018.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

TOPADUR Pharma AG is a Swiss-based biotech company located in Schlieren. TOPADUR is a patient-oriented biotech company that aims to enhance the quality of life through cutting-edge research. The private company is developing a new class of compounds based on their innovative cgmp-enzyme regulation system, which corrects locally cgmp levels. These compounds target high medical needs and can be used to treat several ageing-related diseases resulting from insufficient local blood-circulation. The company was founded in 2015 by Reto Naef, who has been the CEO since then.

Revolo Biotherapeutics Ltd. develops immunologic and inflammatory medications. It develops disease resetting therapeutics for immuno-inflammatory diseases. The company was founded in 2011 and is headquartered in Stevenage, the United Kingdom.

AL-S Pharma AG engages in the development and marketing of pharmaceutical products. The company was founded by Michael Salzmann on September 19, 2016 and is headquartered in Schlieren, Switzerland.

Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland.

Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland.

CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017.